During viral infection, fusion of the viral envelope with endosomal membranes and nucleocapsid release were thought to be concomitant events. We show here that for the vesicular stomatitis virus they occur sequentially, at two successive steps of the endocytic pathway. Fusion already occurs in transport intermediates between early and late endosomes, presumably releasing the nucleocapsid within the lumen of intra-endosomal vesicles, where it remains hidden. Transport to late endosomes is then required for the nucleocapsid to be delivered to the cytoplasm. This last step, which initiates infection, depends on the late endosomal lipid lysobisphosphatidic acid (LBPA) and its putative effector Alix/AIP1, and is regulated by phosphatidylinositol-3-phosphate (PtdIns(3)P) signalling via the PtdIns(3)P-binding protein Snx16. We conclude that the nucleocapsid is exported into the cytoplasm after the back-fusion of internal vesicles with the limiting membrane of late endosomes, and that this process is controlled by the phospholipids LBPA and PtdIns(3)P and their effectors.
Endocytosed proteins and lipids first appear in early endosomes, from where some molecules are recycled to the cell surface or transported to the trans-Golgi network, while others are routed to late endosomes and lysosomes for degradation 1 . Along the latter route, downregulated proteins, including signalling receptors, are selectively incorporated into intralumenal vesicles of the forming endosomal transport intermediates, which exhibit a typical multivesicular appearance. Both receptor sorting and the invagination process are regulated by PtdIns(3)P signalling via Hrs, which contains the PtdIns(3)P-binding motif FYVE, and by ESCRT-I, -II and -III (endosomal sorting complex required for transport) complexes sequentially 2, 3 . Then, multivesicular endosomal intermediates transport their cargo of intralumenal vesicles towards late endosomes and lysosomes, where intralumenal vesicles will eventually be degraded.
The intralumenal membranes of the multivesicular (or multilamellar) regions of late endosomes, however, also contain molecules that are not destined for degradation. These include tetraspanins 4 , mannose-6-phosphate receptor (MPR) in transit 5 , and MHC class II molecules in antigen-presenting cells 6 , as well as the poorly degradable phospholipid LBPA. LBPA is only found in late endosomes and is involved in protein and lipid transport through this compartment [7] [8] [9] [10] [11] . Little is known about the mechanisms that regulate membrane invagination within late endosomes, except that LBPA itself may control the process via its putative effector Alix 12 , a protein that also interacts with ESCRTs during HIV budding at the plasma membrane 13, 14 .
It has long been known that vesicular stomatitis virus (VSV) and many other enveloped viruses must be endocytosed for infection to proceed, and that virions are then transported along the endocytic pathway towards lysosomes. Beyond early endosomes 15 , but before lysosomes, the acidic pH triggers the fusion of the viral envelope with endosomal membranes, releasing the nucleocapsid into the cytosol, where replication of the viral genome occurs 16 . We recently found that Alix downexpression with short interfering RNAs (siRNAs) inhibits VSV infection 12 , perhaps suggesting that endosomes have an active role in the infection process. By monitoring viral envelope fusion, RNA replication and protein synthesis, we investigate whether endosomal membrane dynamics are involved in the VSV infection pathway in vivo and in nucleocapsid release in vitro.
RESULTS

Time course of viral fusion
To detect fusion, VSV was labelled with self-quenching amounts of the fluorescent long-chain dialkylcarbocyanine dye Dil 17, 18 . After VSV prebinding to the cell surface at 4 °C, cells were incubated at 37 °C, so that endocytosis resumed, and analysed by time-lapse microscopy. Little fluorescent signal was detected in cells that were kept at 4 °C ( Fig. 1a ; frame t = 0), even when incubated at pH 5.0 (Fig. 1b) , as observed in vitro 17 , or in cells incubated at 37 °C in the presence of the vesicular protein ATPase (V-ATPase) inhibitor bafilomycin A1 (Fig. 1b) , confirming the validity cells) was pre-bound to the cell surface (as in a), and then co-endocytosed with rhodamine-dextran for 5 min at 37 °C, followed by a 40-min chase without dextran. Cells were processed for immnofluorescence and labelled with the indicated antibodies. VSV-G colocalized with endocytosed dextran (upper panels; arrowheads), which itself colocalized with LBPA (lower panels; arrowheads). Number of experiments: 3 (b) and 4 (d). Scale bars, 2.5 µm (a) and 4 µm (e).
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of the assay. By contrast, brightly fluorescent spots appeared after incubation at 37 °C in the absence of the drug ( Fig. 1a ; see Supplementary Information, Movies 1 and 2 -sequence is shown both with DIC optics (Movie 1) and Dil fluorescence (Movie 2)). After a short lag time, the fluorescence of individual spots increased rapidly, reaching a maximum after 20-25 min (Fig. 1c) , much like influenza virus 18 . Similarly, the number of cells containing fluorescent spots increased rapidly and then levelled off (Fig. 1d) . Hence, viral fusion might be triggered before most virions reach late endocytic compartments, because it takes 30-60 min for the bulk of an endocytosed tracer -including the glycoprotein G of VSV envelope (VSV-G; Fig. 1e ) -to reach late endosomes and lysosomes in the same baby hamster kidney (BHK) cells 19 .
Fusion occurs in endosomal transport intermediates
Transport from early to late endosomes is facilitated by microtubules 20 (see Supplementary Information, Fig. S1 (outline) ). Consistently, microtubule depolymerization with nocodazole inhibited G-protein degradation, as did inhibition of the V-ATPase, and caused the accumulation of endocytosed tracers beyond early endosomes, but before late endosomes (see Supplementary Information, Fig. S2A, B) . Nocodazole, however, did not affect viral fusion to any significant extent (Fig. 2a, b) . Fluorescence ratio imaging showed that the pH of endosomes containing a pH-sensitive probe after microtubule depolymerization was approximately 5.5 ( Fig. 2c) , as acidic as late endosomes and significantly more acidic than early endosomes (pH 6.2) 20 . Fusion thus occurred within acidic endosomal vesicles, but before late endosomes. These vesicles correspond to the operational definition of endosomal transport intermediates, here referred to as endosomal carrier vesicle/multivesicular body (or ECV/ MVBs) 3 , which accumulate endocytosed VSV-G protein or other tracers in the absence of microtubules 19, 21 .
Transport to late endosomes is required for efficient infection and RNA replication
In contrast to viral fusion (Fig. 2a, b) , infection (G-protein synthesis) was markedly reduced by nocodazole -to the same extent as transport to late endosomes 19, 21 -and restored to control levels upon drug washout A R T I C L E S (Fig. 2d) . This was not due to microtubules having a role in transport of free cytosolic capsids, because nocodazole had no effect on infection (see Supplementary Information, Fig. S3A ) when VSV fusion was artificially induced at the plasma membrane, consistent with previous observations 22 . In these experiments, however, infection was much less efficient (10% of controls), supporting the view that VSV hijacked the endocytic pathway to reach the perinuclear region more efficiently. Under physiological conditions, efficient infection -but not fusion -may thus require transport to late endosomes.
To interfere selectively with late endosome functions [8] [9] [10] [11] 23 , we used our monoclonal antibody against LBPA, which can be internalized by fluid-phase endocytosis and accumulates in late endosomes upon binding to its antigen 8 . The endocytosed antibody, but not control antibodies, inhibited infection with VSV in a dose-dependent manner (Fig. 3a) , but not Sendaï virus (Fig. 3b) , which fuses at the plasma membrane. This inhibition was not due to some indirect effects of the antibody on the virions (Fig. 3c and see Supplementary Information, Fig. S3B ). Strikingly, however, endocytosed anti-LBPA antibodies had little effect on viral fusion (Fig. 3d) even at high doses, further supporting the notion that most fusion events had already occurred in ECV/MVBs before arrival in LBPA-containing late endosomes. When nocodazole was added to cells that had been pre-treated with anti-LBPA antibodies, infection was further reduced when compared with treatment with the drug alone, and returned to the levels obtained with antibody alone upon drug washout (Fig. 4a) . The reduced infection rate that was detected in the presence of nocodazole (Fig. 2d ) might thus be caused by some virions that reached late endosomes even in the absence of microtubules. Indeed, microtubules facilitate transport to late endosomes, but transport continues, albeit inefficiently, after depolymerization 21 . The requirement of VSV for transport to late endosomes is not unique to BHK cells, and was also seen in HeLa (Fig. 7a, f ) and bovine cells (Fig. 4c) -cattle are naturally infected by VSV. Moreover, infection of BHK cells with an HIV type 1 (HIV-1)-derived vector expressing green fluorescent protein (GFP) and pseudotyped with VSV-G protein 24 was also inhibited by endocytosed anti-LBPA antibodies (Fig. 4d) . Because HIV-1 normally fuses at the plasma membrane, these data show that the characteristic features of VSV-G protein are transferable and are responsible for the observed phenotype. Hence, the requirement for transport to late endosomes seems to be dictated by the fusion and transport properties of the G glycoprotein.
To ensure that nocodazole or anti-LBPA antibodies did not interfere somehow with the G-protein biosynthetic pathway, we quantified the replication of viral RNA minus-strand by TaqMan real-time PCR (RT-PCR). Microtubule depolymerization (Fig. 2e) or endocytosed 
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anti-LBPA antibodies (Fig. 4b ) inhibited the synthesis of viral RNA minus-strand (and plus-strand; see Supplementary Information, Fig. S3C ). Altogether, these experiments show that fusion of VSV envelopes and nucleocapsid delivery to the cytosol occur sequentially in ECV/MVBs and late endosomes, respectively.
Intralumenal vesicles: PtdIns(3)P signalling and Hrs
The unexpected finding that fusion and nucleocapsid release were sequential events, combined with the apparently crucial role of multivesicular bodies, prompted us to investigate the possible role of endosomal intralumenal vesicles in fusion and nucleocapsid delivery.
During ECV/MVB biogenesis, both the formation of intralumenal vesicles and the sorting of activated receptors within these invaginations are regulated by PtdIns(3)P signalling via the PtdIns(3)P effector Hrs 3 . Inhibition of phosphatidylinositol-3-OH kinase (PI(3)K) using wortmannin caused endosome vacuolation ( Fig. 5a ; t = 35 min, black arrow) as expected [25] [26] [27] , but did not significantly affect VSV fusion (Fig. 5a, b) . Interestingly, the drug increased the percentage of VSVinfected cells (Fig. 5c ) and, to some extent, RNA replication (Fig. 5d) . But in the presence of nocodazole and wortmannin, both infection ( Fig. 5c ) and RNA replication ( Fig. 5d) were back to the levels measured in untreated control cells. , were infected with HIV-1 pseudotyped with VSV-G and expressing GFP. Twenty hours post-infection (PI), GFP expression was analysed by SDS gel electrophoresis and western blotting using anti-GFP antibodies, or anti-annexin2 antibodies as a loading marker (upper panels). Alternatively, cells were analysed by immunofluorescence using a monoclonal anti-GFP antibody, followed by rhodamine-labelled anti-mouse antibodies. Treated cells show a punctate staining pattern (lower panels), corresponding to the endocytosed anti-LBPA (revealed by the secondary anti-mouse antibody), but not the diffuse GFP staining pattern visible in the control. Number of experiments: 4 (a, b) and 3 (c). Scale bar, 4 µm (d).
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When analysed by electron microscopy, intact viral particles ( Fig. 6a,  b ; arrows) can be identified in longitudinal sections by their characteristic bullet-like shape, and in cross section by the presence of G-protein spikes (Fig. 6a, b , b′; small arrowheads). Such intact virions were rarely seen 45 min after VSV internalization, and then only in early endosomes (Fig. 6a) . By contrast, smaller electron-dense structures without a visible spike-delineated envelope, presumably capsids (compare Fig. 6b′ with d′; Fig. 6c -g, arrows and inserts), were frequently observed within late endosomes (Fig. 6f, g ). Capsids ( Fig. 6c-g; inserts) were present within an electron-lucent space that is separated from the lumen of the endosome itself (containing BSA-gold) by a membrane (small arrows), presumably intralumenal vesicles. Vesicles of a similar diameter were seen in control cells that had not been treated with VSV (data not shown), and similar 'empty' vesicles (without capsids) were evident in the same endosomes (for example, see Fig. 6c ). Moreover, in an independent set of experiments, endosomes were labelled in vivo (with endocytosed G protein bound to anti-G antibodies and 10-nm protein A-gold) 19 , and endosomal fractions were prepared and incubated with 4-nm BSA-gold at 4 °C in vitro. Internal structures with a diameter similar to that of internal vesicles could then be labelled with small BSA-gold (Fig. 6i, j) , suggesting that they represent cross-sections of membrane invaginations with a lumen that is equivalent to the cytoplasmic space, perhaps pre-fission or post-fusion intermediates. Finally, immunogold labelling of cryosections showed that VSV-G was indeed present within internal membranes (Fig. 6h) . Altogether, these observations are thus consistent with our findings that fusion occurs before late endosomes, and further suggest that once fusion has occurred, capsids reside within the lumen of intra-endosomal vesicles. In cells treated with wortmannin, intact virions were occasionally detected in vesicles resembling early endosomes (Fig. 6b, b' ), much like in controls (Fig. 6a) , but capsids were not observed in endosomes, suggesting that once fusion has occurred in wortmannin-treated cells, capsids are rapidly released into the cytoplasm.
Hrs is probably the most important PtdIns(3)P effector that is responsible for both membrane invagination within ECV/MVBs and ubiquitinated receptor sorting within these invaginations. Indeed, treatment with siRNAs against Hrs reduces the number of intralumenal vesicles in endosomes and receptor sorting, as is also observed in yeast and Drosophila melanogaster mutants with impaired Hrs function 2, 28, 29 . Silencing Hrs expression with siRNAs ( Fig. 7a ; inset) decreased VSV infection (Fig. 7a) ; this was not surprising because Hrs downregulation causes major alterations in endocytic transport 28, 29 . Although reduced, infection still occurred efficiently, consistent with findings that VSV may not use a ubiquitinated receptor for infection, in contrast to influenza virus 30 . Interestingly, however, as observed with wortmannin, viral infection was no longer sensitive to microtubule depolymerization in Hrs siRNA-treated cells (Fig. 7a, b) . Because both PI(3)K inhibition 27 and Hrs downregulation 29 inhibit the formation of intralumenal vesicles within ECV/MVBs, our data strongly suggest that these intralumenal vesicles are required for proper delivery of infectious VSV particles to late endosomes.
A dual role for PtdIns(3)P
To explore the possible role of PtdIns(3)P further, we investigated whether infection was sensitive to the expression of the tandem PtdIns(3)P-binding domain FYVE 31 that inhibits receptor sorting but not bulk transport (a) Cells were treated with Dil-labelled VSV and analysed as in Fig. 1a , except that 100 nM wortmannin was added. The figure shows frames captured at the indicated times. The black arrow points to vacuoles that appear after wortmannin treatment and small arrows to fusion events, as in Fig. 1a. (b) Cells were treated as in a with or without wortmannin. The number of cells containing fused viruses was counted at the indicated times during the 37 °C incubation, 35 min post-infection, and is expressed as in Fig. 2b. (c, d) VSV at the indicated MOI was endocytosed with or without nocodazole, as in Fig. 2d , except that cells were treated with 100 nM wortmannin 5 min after raising the temperature to 37 °C. Wortmannin was omitted during the initial 5 min, because the drug inhibits internalization. In c, cells were analysed by fluorescence microscopy, and infected and non-infected cells were quantified as in Fig. 2d , whereas in d, replication of viral RNA was measured as in In this analysis, large virus amounts (100 µg per 10 6 cells) were used, because VSV could not be detected by electron microscopy at the low doses used for infection and RNA release. (a-h) After pre-binding to the surface (Fig. 2d) , VSV was co-endocytosed with (f, g) or without (a-e, h) 10-nm BSA-gold (A 520 = 1.7) for 10 min at 37 °C, and then for 40 min without BSA-gold, in BHK cells either treated (b) or not treated (a, c-h) with wortmannin. Cells were then processed for electron microscopy. (a, b) These panels show endosomes (empty arrowheads point to the membrane) that are largely devoid of internal vesicles, presumably early endosomes, which contain both bullet-shaped virions and virions viewed in crosssection (arrows). Small arrowheads indicate G-protein spikes. (c-e) Electron-dense structures without a visible spike-delineated envelope, presumably capsids (arrows), are found within internal vesicles (see insets and the boxed area in d shown in d′; note the clear membrane indicated by arrowheads in d′) of late endosomes identified by their characteristic morphology. (f, g) Cells were treated as in c-e, but a pulse of BSA-gold was endocytosed for 10 min at 37 °C and then chased for 45 min, so that late endosomes could be identified by the gold particles in their lumen. Late endosomes exhibit the characteristic morphology of this compartment in BHK cells 19 , including abundant internal membranes and large electron-lucent elements, perhaps of lipidic origin. (h) This experiment was conducted as in a, then the G-protein distribution was analysed by immunogold labelling of cryosections using anti-VSV-G antibodies (empty arrowheads point to the membrane). Note the characteristic electron-lucent space that is also observed in plastic-embedded samples (c-g). (i, j) The G protein was endocytosed for 45 min at 37 °C into BHK cells 19 after labelling at the cell surface with a polyclonal antibody against the G protein and then with 10-nm protein A-gold. Endosomal fractions were then prepared and incubated in vitro (as in Fig. 8a ) at 4 °C with 4-nm BSA-gold, and processed for electron microscopy. Note that BSA-gold labels apparently internal structures (arrows), which must have continuity with the limiting membrane (and are equivalent to cytoplasmic space) out of the plane of section. Scale bars, 0.2 µm (a-j) and 0.05 µm (b′, d′).
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to late endosomes 32 . In marked contrast to PI(3)K inhibition, tandem FYVE construct (2 × FYVE) inhibited infection (Fig. 7c) without affecting G-protein transport to late endosomes containing LBPA (quantification in Fig. 7d ) or viral fusion (Fig. 7e) , and did not render infection insensitive to microtubule depolymerization (Fig. 7f) . These effects were specific to PtdIns(3)P, because overexpression of the pleckstrin homology (PH) domain of phospholipase Cδ (PLC-δ), which binds PtdIns(4,5)P 2 (ref. 33) , had no effect on VSV infection (Fig. 7c) . We thus reasoned that PtdIns(3)P, in addition to its role in the Hrs-ESCRT pathway, is perhaps also involved in nucleocapsid release from late endosomes -consistent with the presence of PtdIns(3)P on late endosomes 31 -where it may serve as a substrate for the PtdIns(3)P 5-kinase Fab1/PIKfyve 34 . We thus designed an assay that monitors nucleocapsid release in vitro to study the possible role of PtdIns(3)P in the process.
RNA export in vitro
Late endosomes were loaded with VSV in vivo, then endosomal fractions were prepared and incubated in the assay with ATP and cytosol. Endosomes were then separated from the cytosol (presumably containing the released viral RNA) by flotation in sucrose gradients, and RNA was quantified by RT-PCR in cytosol and endosomes (see Supplementary  Information, Figs S3D and S4A ). Viral RNA export from late endosomes occurred efficiently (30% of the amount originally present in endosomes) at 37 °C, but not at 4 °C, and required the presence of ATP and cytosol (Fig. 8a) . Moreover, 90% of endocytosed horseradish peroxidase (HRP; as a marker for the endosomal content) remained entrapped within endosomes during the assay, indicating that RNA was not released because of some damage caused to the endosomes. Finally, viral RNA export was inhibited by the addition of excess purified recombinant Alix or cytosol prepared from cells overexpressing Alix (Fig. 8f) , consistent with our 
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previous in vivo observations 12 . Altogether, these observations show that our assay faithfully reconstitutes the release of viral nucleocapsids, and indicate that Alix controls the process directly, presumably by regulating the dynamics of late endosome internal membranes 12 .
Snx16 acts as PtdIns(3)P effector in nucleocapsid export
Consistent with the inhibitory effects of the tandem FYVE on infection in vivo (Fig. 7c) , RNA export from late endosomes in vitro was efficiently inhibited by cytosol prepared from cells overexpressing GFP-2 × FYVE or, even more so, by purified recombinant glutathione S-transferase (GST)-2 × FYVE (Fig. 8f) . Effects were specific, because no inhibition was observed with the purified recombinant GST-2 × FYVE C125S mutant (Fig. 8f) , which does not bind PtdIns(3)P (ref. 31) , or the PI(4,5)P 2 -binding domain PH of PLC-δ (Fig. 8f) , as seen in vivo (Fig. 7c) . Phox (PX cyt). Alternatively, the assay was performed with control cytosol supplemented with 0.5 µg purified, recombinant Alix,
). Number of experiments: 6 (a), 3 (b-e) and 4 (f). Scale bar, 2.5 µm (c).
In addition, inhibition was not due to indirect effects of the FYVE domain, because RNA export was also inhibited by adding cytosol prepared from cells overexpressing the PtdIns(3)P-binding Phox homology (PX) domain of p40 Phox (Fig. 8f) . A screen for PtdIns(3)P effectors that may regulate RNA export identified the sorting nexin Snx16, which contains the PX motif 35 , as a candidate. Overexpressed Snx16 localizes to early and late endosomes and the protein has a role in epidermal growth factor receptor (EGFR) sorting and EGF-induced signalling 36, 37 . Consistently, Myc-tagged Snx16 (expressed at low levels) colocalized with Lamp1 (Fig. 8c) , an abundant protein of both late endosomes and lysosomes 5, 21 , and to a lesser extent with the early endosomal marker EEA1 (see Supplementary Information, Fig. S4B ). Snx16-GFP strongly reduced VSV infection in vivo (Fig. 8e) , without affecting VSV transport to late endosomes containing LBPA (Fig. 8b) . Consistently, overexpressed Snx16 did not prevent, but increased, EGFR degradation 37 . By contrast, the Snx16 R144A mutant, with a single-point mutation in the predicted PtdIns(3)P-binding motif, was largely cytosolic (Fig. 8c) , as expected, and had little effect on VSV infection (Fig. 8e) . Similarly, RNA export was inhibited in vitro by the addition of cytosol from cells overexpressing Snx16, or by purified recombinant Snx16 (Fig. 8d) . Effects were specific, because cytosol prepared from cells overexpressing Hrs had no effect on RNA export in vitro (Fig. 8d) , in agreement with our in vivo observations (Fig. 8e) . Snx16 may thus act as a PtdIns(3)P effector in regulating viral RNA export from late endosomes.
DISCUSSION
We find that the fusion of the enveloped virus VSV and the subsequent release of the viral nucleocapsid into the cytosol occur sequentially, at successive steps of the endocytic pathway (see Supplementary Information,  Fig. S1 ; model). After fusion of the viral envelope, the nucleocapsid is delivered to the lumen of internal vesicles, contained within ECV/MVBs where it remains hidden. The nucleocapsid then travels within these internal vesicles to reach and penetrate late endosomes. There, the back-fusion of internal vesicles with the endosome's limiting membrane delivers the nucleocapsid to the cytoplasm in a process that depends on LBPA under the control of Alix, and PtdIns(3)P signalling via Snx16.
If fusion already occurred in ECV/MVBs, why isn't the nucleocapsid concomitantly delivered to the cytoplasm? And why is transport to late endosomes then needed? Like all endosomes along the degradation pathway, ECV/MVBs accumulate internal membranes and thus exhibit a characteristic multivesicular appearance 1 . When present in the endosomal lumen, virions are thus more likely to interact with these internal membranes than with the limiting membrane, particularly at low (0.1-1.0) multiplicity of infection (MOI), simply because they are far more abundant. Alternatively, VSV that is bound to a putative VSV receptor -perhaps a lipid 38 , consistent with findings that VSV infection does not depend on protein ubiquitination 30 -may be selectively incorporated into internal membranes. In either situation, fusion would cause the release of the nucleocapsid into an internal space, which is topologically equivalent to, but not continuous with, the cytoplasm. Nucleocapsid release into the cytoplasm and infection then require the back-fusion of these intra-endosomal vesicles with the limiting membrane.
Evidence shows that internal vesicles and their cargo are degraded in lysosomes. Both in yeast and mammalian cells, the same molecular mechanisms operate on early endosomes to sort downregulated receptors that are destined for lysosomes into these internal membranes, and to drive the biogenesis of these internal membranes 2, 3 . Intralumenal vesicles also accumulate in the vacuole of yeast degradation mutants 2 . Nucleocapsid delivery into the lumen of internal vesicles would then be a dead end leading to degradation in lysosomes rather than infection.
Several lines of evidence indicate that internal membranes of late endosomes in animal cells also contain proteins and lipids that are not destined for the lysosomes, including, in particular, LBPA itself, which is both poorly degraded and abundant in internal membranes; whether this lipid is present in yeast is not known. Moreover, MHC class II molecules, which are predominantly found within internal membranes of late endosomes in dendritic cells, are rapidly transported to the cell surface upon cell activation. Hence, back-transport from internal membranes occurs, at least in these cells, presumably via tubules 39 that may form at the expense of internal membranes via back-fusion 6 . MPR molecules in transit are also found within late endosome internal membranes 5 , where they accumulate in cells that contain endocytosed antibodies against LBPA 8 . Similarly, these antibodies inhibit cholesterol 23 and nucleocapsid export (this study) from late endosomes. Finally, the delivery of the anthrax toxin lethal factor to the cytoplasm may also rely on the dynamics of internal vesicles of multivesicular late endosomes, and is inhibited by Alix downregulation 40 . We conclude that the nucleocapsid makes use of internal vesicles to reach late endosomes, from where it is efficiently released, through the back-fusion of internal vesicles with the limiting membrane (see Supplementary Information, Fig. S1 ; model). It thus seems that, in addition to the downregulation pathway conserved from yeast to man, animal cells have evolved an elaborate membrane system in late endosomes for efficient re-utilization and sorting of specialized lipid and protein. VSV may have hijacked this pathway to overcome the diffusion barrier imposed by the cortical actin cytoskeleton, to efficiently reach the perinuclear region of the cell.
Although the precise mechanism that leads to nucleocapsid delivery and back-fusion remains to be unravelled, some speculation is already possible. Our previous in vitro observations suggested that LBPA can trigger membrane invagination in late endosomes, and that Alix controls this process 12 -Alix can interact with ESCRTs 13, 14 and may function in concert with, or downstream of, the ESCRT-III complex in yeast 41 . We now find that Alix is also required for efficient nucleocapsid release, suggesting that invagination and back-fusion are coupled mechanistically via Alix. Further support for such molecular coupling comes from observations that PtdIns(3)P signalling regulates the invagination process via Hrs 2, 28, 29 , and perhaps back-fusion via Snx16 (this study). Members of the Snx family contain a BAR domain that may sense membrane curvature and also bind small GTPases 42, 43 . Whether Snx16 contains a BAR domain is not known. But we may speculate that the protein functions as a sensor or as a regulator of endosomal membrane curvature or dynamics. Alix and Snx16 may thus act in tandem to maintain the homeostasis of internal membranes in the endosomal lumen.
Clearly, the molecular events that regulate fission and fusion within the endosomal lumen remain to be elucidated. It is far from clear how these processes can be controlled by cytosolic machineries from the opposite side of the membrane, as is the case with coat proteins and SNAREs in intracellular transport. Our previously published data argue that these intralumenal fission and fusion events may depend, at least in part, on the intrinsic properties of the bilayer itself, via LBPA 12, 44 .
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LBPA-rich membranes may have a high propensity to interact spontaneously with the limiting bilayer, involving some sort of kiss-and-run fission and fusion events. Alix in turn may negatively control the invagination process by binding LBPA-rich membranes 44 . Thus, a naïve view is that Alix interacts with LBPA as the lipid appears on the limiting bilayer during back-fusion, and by trapping this fusion intermediate controls the rates of subsequent rounds of fission and fusion. This view may provide a simple explanation for the coupling that must exist in this process between invagination and back-fusion -if uncoupled, the internal membrane pool would disappear due to uncontrolled back-fusion, or the organelle would collapse due to uncontrolled fission.
METHODS
Cells, antibodies and reagents. BHK cells were grown and maintained as described 19 , as was the production and purification of VSV (Indiana serotype) Plasmids, RNA interference and transfection. The plasmid containing Hrs-Myc was obtained from H. Stenmark (Oslo, Norway). The production of GFP-2 × FYVE and the purification of recombinant GST-2 × FYVE and GST-2 × FYVE C215S were described previously 31, 32 . The PX domains from pET32a-p40 Phox (Marie-Claire Dagher, Grenoble, France) were amplified by PCR and introduced into pEGFPC2 after EcoRI-SalI digestion. PGEX4T-1-Snx16 and pDmyc-Snx16 were obtained from W. Hong (Singapore); Snx16 cDNA was amplified by PCR and introduced into pEGFPC2 after KpnI-BamH1 digestion. Arg 144, corresponding to Arg 58 in the p40
Phox PX domain, was mutated to alanine (R144A) by site-directed mutagenesis. Hrs expression was silenced by RNAi 29 in HeLa cells transfected with oligofectamine, according to ref. 45 , using annealed 21-nucleotide RNA duplexes with 2-nucleotide 3′-(2-deoxy)thymidine overhangs (obtained from Xeragon, Huntsville, AL). BHK cells were transfected 24 h after seeding with FuGene6 using 1 µg cDNA and incubated for 36 h.
VSV fusion. Dil-labelled VSV 18 was prepared by incubating 200 µl of 2 mg ml −1 VSV in TNE-sucrose buffer supplemented with 2 µl of 25 mM Dil in DMSO, for 2 h at room temperature with gentle mixing. The unbound dye was removed by centrifugation on a step sucrose gradient; the sample in 10% sucrose was layered onto 30% and then 55% sucrose cushions in TNE buffer, and the gradient was centrifuged at 55,000g for 90 min at 4 °C. The labelled virus was collected on top of the 55% sucrose cushion. Immediately before the experiments, possible viral aggregates were removed by filtration (0.22 µm pore size), and viral aggregates were never observed in our experiments (Fig. 1 ). This labelling procedure barely affected the virus infectious titre (see Supplementary Information, Fig. S4C 46 . Alternatively, cells were pre-treated overnight at 37 °C with 5 or 50 µg ml −1 6C4 antibody. To quantify VSV replication, cells were infected with 0.1 MOI, as above. A postnuclear supernatant (PNS) was then prepared, diluted twice in PK buffer (200 mM NaCl, 200 mM Tris pH 9.0, 20 mM EDTA, 2% SDS), and incubated with 2 µg µl −1 proteinase K. Total RNA was extracted with phenol-chloroform and precipitated with 2 M NaCl and 100% ethanol. Next, 0.5 µg total RNA was used for retrotranscription with Superscript RT (Invitrogen, Scotland, UK). To retrotranscribe the genomic VSV-G RNA, we chose the following oligonucleotide: 5′-TTACCATTATTGGCCCGTCAAGCT-3′. The transcribed DNA was then subjected to TaqMan RT-PCR using the following two primers and a fluorescent probe: forward primer, 5′-AGG CAC AGC CAT ACA AGT CAA A-3′; reverse primer, 5′-TTT GGA AGC ATG ACA CAT CCA-3′; probe, 5′-CCG TCT GCT TGA ATA GCC TTG TGA CTC TTG-3′. The probe was modified by addition of 6-carboxyfluoroscein (6-FAM) at the 5′ end and 6-carboxy-tetramethyl-rhodamine (TAMRA) at the 3′ end. For TaqMan RT-PCR we used the ICycler.IQ (BioRad, Hercules, CA). When indicated, BHK cells, pre-treated or not with 50 µg ml −1 anti-LBPA antibodies, were incubated for 1 h at 4 °C with an HIV-1-derived vector expressing GFP, and pseudotyped with VSV-G protein (3 µl of a 10 9 pfu ml −1 stock for 10 6 cells) 24 . BHK cells were then incubated for 20 h at 37 °C with or without the antibody. GFP expression was analysed by indirect immunofluorescence or SDS gel electrophoresis and western blotting using a monoclonal anti-GFP antibody. Alternatively, cells were infected with 1 MOI (10 5 pfu ml −1 ) recombinant Sendaï virus expressing RFP for 14 h at 37 °C. pH measurements. Subconfluent BHK cells grown on glass coverslips and treated with 10 µM nocodazole as above, were incubated with 10 µg ml −1 BCECF-dextran (a pH-sensitive dye) for 15 min at 37 °C followed by a 30-min chase to accumulate the dye in ECV/MVBs. The endosomal pH was measured by ratio fluorescence imaging 47 . We used the Nipkow QLC100 real-time confocal system (Visitron systems GmbH, Puchheim, Germany). Coverslips were inserted into a perfusion chamber with a controlled temperature. Calibration and image processing were described 48 .
Nucleocapsid release in vitro. VSV (1 µg VSV per 1.3 × 10 7 cells) was bound for 1 h at 4 °C to the surface of BHK cells, which had been pre-treated for 2 h with 10 µM nocodazole. Cells were then incubated for 45 min at 37 °C in GMEM containing 10 µM nocodazole, washed three times with PBS at 37 °C, and reincubated first for 10 min in medium without drugs and then for 30 min with 100 nM of the reversible V-ATPase inhibitor concanamycin B, to ensure that viral fusion, if at all, would not occur in late endosomes. Concanamycin B was omitted during the first incubation step to limit the risk that it might interfere with transport itself 46 . Cells were washed three times at 4 °C with PBS, and fractions containing both early and late endosomes were prepared 49 . In the assay, 60 µl fraction was mixed with 4.5 µl concentrated salt solution (0.625 M HEPES pH 7.0, 75 mM MgOAC 2 , 50 mM DTT), 18 µl 1 M KCl, 120 µg HeLa cytosol, and 6U apyrase or ATP regenerating system 21 . After 20 min at 37 °C, the mixture was loaded at the bottom of a step sucrose gradient 21 , and centrifuged at 100,000g for 1 h (TLS 55 rotor). The load (containing released viral RNA) and the interface A R T I C L E S (containing endosomes with non-released viral RNA) were then collected. RNA was extracted from each fraction and quantified by RT-PCR, as above. Cytosol was prepared from PNSs of untransfected or transfected HeLa cells, which had been complemented with protease inhibitors (10 µM leupeptin, 1 µM aprotinin, 1 µM pepstatin) by centrifugation at 100,000g for 1 h. The supernatant (cytosol) was collected, aliquoted, flash-frozen and stored at −90 °C.
Microscopy. Electron microscopy after plastic embedding 50 and immunofluorescence 8 were as described previously. For in vitro incubation of endosomes with 4-nm BSA-gold, endosomal fractions (prepared as above) were incubated with highly concentrated BSA-gold (absorbance at 520 nm (A 520 ) = 40) for 30 min at 4 °C, as described for nucleocapsid release. Figure S4 (A) Trypsin-protection of viral RNA. Endosomal fractions loaded with VSV were used in the assay measuring RNA release in vitro ( Fig  8A) . Pre-incubation of endosomes with 0.1mg TPCK-treated trypsin/mg endosomal protein did not affect viral RNA export in vitro (measured by RT-PCR, Fig 8A) , indicating that viral capsids were protease-resistant, and thus contained within the endosomal lumen. Similarly, trypsin treatment of the cytosol (cyt) was without effect. However, trypsin treatment of both cytosol and membranes inhibited RNA export, presumably because some factors that cycle between cytosol and membranes were then degraded, consistently with the role of Alix and SNX16 in the export process. Effects of trypsin were abolished by the concomitant addition of stoechiometric amounts of soybean trypsin inhibitor. Hence, the viral RNA present in endosomal fractions was not released by trypsin treatment of the membranes, indicating that capsids were present within endosomes, and not peripherally associated. (B). SNX16-GFP colocalizes only partially with EEA1. GFP-tagged Snx16 was expressed in HeLa cells, as in Fig 8C. Cells were then processed for immunofluorescence using antibodies against EEA1 and examined by double channel fluorescence. Many SNX16-containing vesicles (arrowheads) are not labeled by anti-EEA1 antibodies (arrows), under our conditions of low SNX16 expression. (C) Infectivity of DIL-labeled VSV compared to controls. VSV was labeled with DIL (Methods), and then the number of infectious particles was determined and compared to untreated controls (see above, calculation of VSV titers, and MOI). DIL-labeling caused a small reduction in VSV infectivity (expressed as a percentage of controls).
